article thumbnail

Scleroderma drug trial shows up to 60% improvement

Drug Discovery World

Professor Dinesh Khanna, Frederick GL Huetwell Professor of Rheumatology and Director, Scleroderma Program at the University of Michigan said: “The mechanism of action for FT011 offers an important point of difference for the scleroderma research field as the upstream inhibition of inflammation and fibrosis may offer meaningful clinical outcomes.

article thumbnail

Small Pharma stock market launch funds DMT-based depression drug trial

pharmaphorum

DMT is a powerful hallucinogenic drug found in several plants including the South American plant chacruna and when used recreationally is mixed with the ayahuasca plant to make the shamanic brew of the same name. The post Small Pharma stock market launch funds DMT-based depression drug trial appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scepticism in press over Kintor’s COVID-19 US drug trial

pharmaphorum

China’s Kintor Pharmaceutical has begun late-stage US clinical development of its potential COVID drug proxalutamide – but there is scepticism over the company’s claims about its research. The post Scepticism in press over Kintor’s COVID-19 US drug trial appeared first on.

article thumbnail

Avacta opens two US sites and doses first patient in sarcoma drug trial

Outsourcing Pharma

TWO US clinical investigator sites have been opened for a phase 1 clinical trial for patients with soft tissue sarcoma and the first patient has been dosed.

article thumbnail

This week in drug discovery (6-10 February)

Drug Discovery World

Clinical drug trials have made the headlines this week, as it was revealed that breast cancer still tops the bill for number of clinical studies and the shortcomings in current methods to ensure representation of patient populations in trials were exposed.

Drugs 52
article thumbnail

Vicore initiates clinical proof-of-concept study of endothelial dysfunction 

Drug Discovery World

Official comments “Measuring endothelial dysfunction with the EndoPAT technology in drug trials is a cost-effective and robust method for early documentation of proof-of-concept in pulmonary, renal and vascular diseases” says Elin Rosendahl, VP Clinical Operations, Vicore Pharma.

article thumbnail

International Women’s Day: Female life science leaders

Drug Discovery World

Livia Ng, CEO and Founder, Neuroute At just 24 years old, Ng is working on critical challenges in clinical trials, specifically in planning and recruitment, and has been building innovative solutions designed to benefit patients and researchers – with a focus on efficiency, transparency and diversity in clinical development.